img

Global Neoantigen Vaccine Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neoantigen Vaccine Market Research Report 2024

According to Mr Accuracy reports’s new survey, global Neoantigen Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neoantigen Vaccine market research.
Key companies engaged in the Neoantigen Vaccine industry include Pfizer, Merck & Co Inc, Eli Lilly and Company, BioNTech, Roche Holding AG, OSE Immunotherapeutics, Gritstone Bio, Moderna and Avidea Technologies, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Neoantigen Vaccine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Neoantigen Vaccine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neoantigen Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom
Segment by Type
Personalized Vaccine
Off-the shelf Vaccine

Segment by Application


Lung Cancer
Melanoma Cancer
Gastrointestinal Cancer
Brain Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Neoantigen Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Vaccine Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 Personalized Vaccine
1.2.3 Off-the shelf Vaccine
1.3 Market by Application
1.3.1 Global Neoantigen Vaccine Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Lung Cancer
1.3.3 Melanoma Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Brain Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Vaccine Market Perspective (2024-2034)
2.2 Neoantigen Vaccine Growth Trends by Region
2.2.1 Global Neoantigen Vaccine Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 Neoantigen Vaccine Historic Market Size by Region (2024-2024)
2.2.3 Neoantigen Vaccine Forecasted Market Size by Region (2024-2034)
2.3 Neoantigen Vaccine Market Dynamics
2.3.1 Neoantigen Vaccine Industry Trends
2.3.2 Neoantigen Vaccine Market Drivers
2.3.3 Neoantigen Vaccine Market Challenges
2.3.4 Neoantigen Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Vaccine Players by Revenue
3.1.1 Global Top Neoantigen Vaccine Players by Revenue (2024-2024)
3.1.2 Global Neoantigen Vaccine Revenue Market Share by Players (2024-2024)
3.2 Global Neoantigen Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Vaccine Revenue
3.4 Global Neoantigen Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Vaccine Revenue in 2022
3.5 Neoantigen Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Vaccine Breakdown Data by Type
4.1 Global Neoantigen Vaccine Historic Market Size by Type (2024-2024)
4.2 Global Neoantigen Vaccine Forecasted Market Size by Type (2024-2034)
5 Neoantigen Vaccine Breakdown Data by Application
5.1 Global Neoantigen Vaccine Historic Market Size by Application (2024-2024)
5.2 Global Neoantigen Vaccine Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Neoantigen Vaccine Market Size (2024-2034)
6.2 North America Neoantigen Vaccine Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America Neoantigen Vaccine Market Size by Country (2024-2024)
6.4 North America Neoantigen Vaccine Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neoantigen Vaccine Market Size (2024-2034)
7.2 Europe Neoantigen Vaccine Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe Neoantigen Vaccine Market Size by Country (2024-2024)
7.4 Europe Neoantigen Vaccine Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Vaccine Market Size (2024-2034)
8.2 Asia-Pacific Neoantigen Vaccine Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific Neoantigen Vaccine Market Size by Region (2024-2024)
8.4 Asia-Pacific Neoantigen Vaccine Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neoantigen Vaccine Market Size (2024-2034)
9.2 Latin America Neoantigen Vaccine Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America Neoantigen Vaccine Market Size by Country (2024-2024)
9.4 Latin America Neoantigen Vaccine Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Vaccine Market Size (2024-2034)
10.2 Middle East & Africa Neoantigen Vaccine Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa Neoantigen Vaccine Market Size by Country (2024-2024)
10.4 Middle East & Africa Neoantigen Vaccine Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neoantigen Vaccine Introduction
11.1.4 Pfizer Revenue in Neoantigen Vaccine Business (2024-2024)
11.1.5 Pfizer Recent Development
11.2 Merck & Co Inc
11.2.1 Merck & Co Inc Company Detail
11.2.2 Merck & Co Inc Business Overview
11.2.3 Merck & Co Inc Neoantigen Vaccine Introduction
11.2.4 Merck & Co Inc Revenue in Neoantigen Vaccine Business (2024-2024)
11.2.5 Merck & Co Inc Recent Development
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Detail
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Neoantigen Vaccine Introduction
11.3.4 Eli Lilly and Company Revenue in Neoantigen Vaccine Business (2024-2024)
11.3.5 Eli Lilly and Company Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech Neoantigen Vaccine Introduction
11.4.4 BioNTech Revenue in Neoantigen Vaccine Business (2024-2024)
11.4.5 BioNTech Recent Development
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Detail
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Neoantigen Vaccine Introduction
11.5.4 Roche Holding AG Revenue in Neoantigen Vaccine Business (2024-2024)
11.5.5 Roche Holding AG Recent Development
11.6 OSE Immunotherapeutics
11.6.1 OSE Immunotherapeutics Company Detail
11.6.2 OSE Immunotherapeutics Business Overview
11.6.3 OSE Immunotherapeutics Neoantigen Vaccine Introduction
11.6.4 OSE Immunotherapeutics Revenue in Neoantigen Vaccine Business (2024-2024)
11.6.5 OSE Immunotherapeutics Recent Development
11.7 Gritstone Bio
11.7.1 Gritstone Bio Company Detail
11.7.2 Gritstone Bio Business Overview
11.7.3 Gritstone Bio Neoantigen Vaccine Introduction
11.7.4 Gritstone Bio Revenue in Neoantigen Vaccine Business (2024-2024)
11.7.5 Gritstone Bio Recent Development
11.8 Moderna
11.8.1 Moderna Company Detail
11.8.2 Moderna Business Overview
11.8.3 Moderna Neoantigen Vaccine Introduction
11.8.4 Moderna Revenue in Neoantigen Vaccine Business (2024-2024)
11.8.5 Moderna Recent Development
11.9 Avidea Technologies
11.9.1 Avidea Technologies Company Detail
11.9.2 Avidea Technologies Business Overview
11.9.3 Avidea Technologies Neoantigen Vaccine Introduction
11.9.4 Avidea Technologies Revenue in Neoantigen Vaccine Business (2024-2024)
11.9.5 Avidea Technologies Recent Development
11.10 Vaccibody AS
11.10.1 Vaccibody AS Company Detail
11.10.2 Vaccibody AS Business Overview
11.10.3 Vaccibody AS Neoantigen Vaccine Introduction
11.10.4 Vaccibody AS Revenue in Neoantigen Vaccine Business (2024-2024)
11.10.5 Vaccibody AS Recent Development
11.11 Agenus Inc
11.11.1 Agenus Inc Company Detail
11.11.2 Agenus Inc Business Overview
11.11.3 Agenus Inc Neoantigen Vaccine Introduction
11.11.4 Agenus Inc Revenue in Neoantigen Vaccine Business (2024-2024)
11.11.5 Agenus Inc Recent Development
11.12 Novogene
11.12.1 Novogene Company Detail
11.12.2 Novogene Business Overview
11.12.3 Novogene Neoantigen Vaccine Introduction
11.12.4 Novogene Revenue in Neoantigen Vaccine Business (2024-2024)
11.12.5 Novogene Recent Development
11.13 ZIOPHARM Oncology
11.13.1 ZIOPHARM Oncology Company Detail
11.13.2 ZIOPHARM Oncology Business Overview
11.13.3 ZIOPHARM Oncology Neoantigen Vaccine Introduction
11.13.4 ZIOPHARM Oncology Revenue in Neoantigen Vaccine Business (2024-2024)
11.13.5 ZIOPHARM Oncology Recent Development
11.14 ISA Pharmaceuticals
11.14.1 ISA Pharmaceuticals Company Detail
11.14.2 ISA Pharmaceuticals Business Overview
11.14.3 ISA Pharmaceuticals Neoantigen Vaccine Introduction
11.14.4 ISA Pharmaceuticals Revenue in Neoantigen Vaccine Business (2024-2024)
11.14.5 ISA Pharmaceuticals Recent Development
11.15 BrightPath Biotherapeutics
11.15.1 BrightPath Biotherapeutics Company Detail
11.15.2 BrightPath Biotherapeutics Business Overview
11.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Introduction
11.15.4 BrightPath Biotherapeutics Revenue in Neoantigen Vaccine Business (2024-2024)
11.15.5 BrightPath Biotherapeutics Recent Development
11.16 Vaximm AG
11.16.1 Vaximm AG Company Detail
11.16.2 Vaximm AG Business Overview
11.16.3 Vaximm AG Neoantigen Vaccine Introduction
11.16.4 Vaximm AG Revenue in Neoantigen Vaccine Business (2024-2024)
11.16.5 Vaximm AG Recent Development
11.17 Medigene AG
11.17.1 Medigene AG Company Detail
11.17.2 Medigene AG Business Overview
11.17.3 Medigene AG Neoantigen Vaccine Introduction
11.17.4 Medigene AG Revenue in Neoantigen Vaccine Business (2024-2024)
11.17.5 Medigene AG Recent Development
11.18 Genocea Biosciences Inc
11.18.1 Genocea Biosciences Inc Company Detail
11.18.2 Genocea Biosciences Inc Business Overview
11.18.3 Genocea Biosciences Inc Neoantigen Vaccine Introduction
11.18.4 Genocea Biosciences Inc Revenue in Neoantigen Vaccine Business (2024-2024)
11.18.5 Genocea Biosciences Inc Recent Development
11.19 Advaxis
11.19.1 Advaxis Company Detail
11.19.2 Advaxis Business Overview
11.19.3 Advaxis Neoantigen Vaccine Introduction
11.19.4 Advaxis Revenue in Neoantigen Vaccine Business (2024-2024)
11.19.5 Advaxis Recent Development
11.20 Nouscom
11.20.1 Nouscom Company Detail
11.20.2 Nouscom Business Overview
11.20.3 Nouscom Neoantigen Vaccine Introduction
11.20.4 Nouscom Revenue in Neoantigen Vaccine Business (2024-2024)
11.20.5 Nouscom Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neoantigen Vaccine Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the shelf Vaccine
Table 4. Global Neoantigen Vaccine Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 5. Global Neoantigen Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 6. Global Neoantigen Vaccine Market Size by Region (2024-2024) & (US$ Million)
Table 7. Global Neoantigen Vaccine Market Share by Region (2024-2024)
Table 8. Global Neoantigen Vaccine Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 9. Global Neoantigen Vaccine Market Share by Region (2024-2034)
Table 10. Neoantigen Vaccine Market Trends
Table 11. Neoantigen Vaccine Market Drivers
Table 12. Neoantigen Vaccine Market Challenges
Table 13. Neoantigen Vaccine Market Restraints
Table 14. Global Neoantigen Vaccine Revenue by Players (2024-2024) & (US$ Million)
Table 15. Global Neoantigen Vaccine Market Share by Players (2024-2024)
Table 16. Global Top Neoantigen Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Vaccine as of 2022)
Table 17. Ranking of Global Top Neoantigen Vaccine Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Neoantigen Vaccine Revenue (CR5 and HHI) & (2024-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neoantigen Vaccine Product Solution and Service
Table 21. Date of Enter into Neoantigen Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Vaccine Market Size by Type (2024-2024) & (US$ Million)
Table 24. Global Neoantigen Vaccine Revenue Market Share by Type (2024-2024)
Table 25. Global Neoantigen Vaccine Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 26. Global Neoantigen Vaccine Revenue Market Share by Type (2024-2034)
Table 27. Global Neoantigen Vaccine Market Size by Application (2024-2024) & (US$ Million)
Table 28. Global Neoantigen Vaccine Revenue Market Share by Application (2024-2024)
Table 29. Global Neoantigen Vaccine Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 30. Global Neoantigen Vaccine Revenue Market Share by Application (2024-2034)
Table 31. North America Neoantigen Vaccine Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 32. North America Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 33. North America Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 34. Europe Neoantigen Vaccine Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 35. Europe Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 36. Europe Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 37. Asia-Pacific Neoantigen Vaccine Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 38. Asia-Pacific Neoantigen Vaccine Market Size by Region (2024-2024) & (US$ Million)
Table 39. Asia-Pacific Neoantigen Vaccine Market Size by Region (2024-2034) & (US$ Million)
Table 40. Latin America Neoantigen Vaccine Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 41. Latin America Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 42. Latin America Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 43. Middle East & Africa Neoantigen Vaccine Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 44. Middle East & Africa Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 45. Middle East & Africa Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Neoantigen Vaccine Product
Table 49. Pfizer Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Merck & Co Inc Company Detail
Table 52. Merck & Co Inc Business Overview
Table 53. Merck & Co Inc Neoantigen Vaccine Product
Table 54. Merck & Co Inc Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 55. Merck & Co Inc Recent Development
Table 56. Eli Lilly and Company Company Detail
Table 57. Eli Lilly and Company Business Overview
Table 58. Eli Lilly and Company Neoantigen Vaccine Product
Table 59. Eli Lilly and Company Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 60. Eli Lilly and Company Recent Development
Table 61. BioNTech Company Detail
Table 62. BioNTech Business Overview
Table 63. BioNTech Neoantigen Vaccine Product
Table 64. BioNTech Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 65. BioNTech Recent Development
Table 66. Roche Holding AG Company Detail
Table 67. Roche Holding AG Business Overview
Table 68. Roche Holding AG Neoantigen Vaccine Product
Table 69. Roche Holding AG Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 70. Roche Holding AG Recent Development
Table 71. OSE Immunotherapeutics Company Detail
Table 72. OSE Immunotherapeutics Business Overview
Table 73. OSE Immunotherapeutics Neoantigen Vaccine Product
Table 74. OSE Immunotherapeutics Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 75. OSE Immunotherapeutics Recent Development
Table 76. Gritstone Bio Company Detail
Table 77. Gritstone Bio Business Overview
Table 78. Gritstone Bio Neoantigen Vaccine Product
Table 79. Gritstone Bio Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 80. Gritstone Bio Recent Development
Table 81. Moderna Company Detail
Table 82. Moderna Business Overview
Table 83. Moderna Neoantigen Vaccine Product
Table 84. Moderna Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 85. Moderna Recent Development
Table 86. Avidea Technologies Company Detail
Table 87. Avidea Technologies Business Overview
Table 88. Avidea Technologies Neoantigen Vaccine Product
Table 89. Avidea Technologies Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 90. Avidea Technologies Recent Development
Table 91. Vaccibody AS Company Detail
Table 92. Vaccibody AS Business Overview
Table 93. Vaccibody AS Neoantigen Vaccine Product
Table 94. Vaccibody AS Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 95. Vaccibody AS Recent Development
Table 96. Agenus Inc Company Detail
Table 97. Agenus Inc Business Overview
Table 98. Agenus Inc Neoantigen Vaccine Product
Table 99. Agenus Inc Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 100. Agenus Inc Recent Development
Table 101. Novogene Company Detail
Table 102. Novogene Business Overview
Table 103. Novogene Neoantigen Vaccine Product
Table 104. Novogene Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 105. Novogene Recent Development
Table 106. ZIOPHARM Oncology Company Detail
Table 107. ZIOPHARM Oncology Business Overview
Table 108. ZIOPHARM Oncology Neoantigen Vaccine Product
Table 109. ZIOPHARM Oncology Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 110. ZIOPHARM Oncology Recent Development
Table 111. ISA Pharmaceuticals Company Detail
Table 112. ISA Pharmaceuticals Business Overview
Table 113. ISA Pharmaceuticals Neoantigen Vaccine Product
Table 114. ISA Pharmaceuticals Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 115. ISA Pharmaceuticals Recent Development
Table 116. BrightPath Biotherapeutics Company Detail
Table 117. BrightPath Biotherapeutics Business Overview
Table 118. BrightPath Biotherapeutics Neoantigen Vaccine Product
Table 119. BrightPath Biotherapeutics Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 120. BrightPath Biotherapeutics Recent Development
Table 121. Vaximm AG Company Detail
Table 122. Vaximm AG Business Overview
Table 123. Vaximm AG Neoantigen Vaccine Product
Table 124. Vaximm AG Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 125. Vaximm AG Recent Development
Table 126. Medigene AG Company Detail
Table 127. Medigene AG Business Overview
Table 128. Medigene AG Neoantigen Vaccine Product
Table 129. Medigene AG Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 130. Medigene AG Recent Development
Table 131. Genocea Biosciences Inc Company Detail
Table 132. Genocea Biosciences Inc Business Overview
Table 133. Genocea Biosciences Inc Neoantigen Vaccine Product
Table 134. Genocea Biosciences Inc Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 135. Genocea Biosciences Inc Recent Development
Table 136. Advaxis Company Detail
Table 137. Advaxis Business Overview
Table 138. Advaxis Neoantigen Vaccine Product
Table 139. Advaxis Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 140. Advaxis Recent Development
Table 141. Nouscom Company Detail
Table 142. Nouscom Business Overview
Table 143. Nouscom Neoantigen Vaccine Product
Table 144. Nouscom Revenue in Neoantigen Vaccine Business (2024-2024) & (US$ Million)
Table 145. Nouscom Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Vaccine Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Neoantigen Vaccine Market Share by Type: 2022 VS 2034
Figure 3. Personalized Vaccine Features
Figure 4. Off-the shelf Vaccine Features
Figure 5. Global Neoantigen Vaccine Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 6. Global Neoantigen Vaccine Market Share by Application: 2022 VS 2034
Figure 7. Lung Cancer Case Studies
Figure 8. Melanoma Cancer Case Studies
Figure 9. Gastrointestinal Cancer Case Studies
Figure 10. Brain Cancer Case Studies
Figure 11. Others Case Studies
Figure 12. Neoantigen Vaccine Report Years Considered
Figure 13. Global Neoantigen Vaccine Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 14. Global Neoantigen Vaccine Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 15. Global Neoantigen Vaccine Market Share by Region: 2022 VS 2034
Figure 16. Global Neoantigen Vaccine Market Share by Players in 2022
Figure 17. Global Top Neoantigen Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neoantigen Vaccine as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Neoantigen Vaccine Revenue in 2022
Figure 19. North America Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 20. North America Neoantigen Vaccine Market Share by Country (2024-2034)
Figure 21. United States Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 22. Canada Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 23. Europe Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 24. Europe Neoantigen Vaccine Market Share by Country (2024-2034)
Figure 25. Germany Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 26. France Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 27. U.K. Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 28. Italy Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. Russia Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. Nordic Countries Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 31. Asia-Pacific Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 32. Asia-Pacific Neoantigen Vaccine Market Share by Region (2024-2034)
Figure 33. China Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 34. Japan Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 35. South Korea Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 36. Southeast Asia Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. India Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. Australia Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 39. Latin America Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 40. Latin America Neoantigen Vaccine Market Share by Country (2024-2034)
Figure 41. Mexico Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 42. Brazil Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 43. Middle East & Africa Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 44. Middle East & Africa Neoantigen Vaccine Market Share by Country (2024-2034)
Figure 45. Turkey Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 46. Saudi Arabia Neoantigen Vaccine Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 48. Merck & Co Inc Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 49. Eli Lilly and Company Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 50. BioNTech Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 51. Roche Holding AG Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 52. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 53. Gritstone Bio Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 54. Moderna Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 55. Avidea Technologies Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 56. Vaccibody AS Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 57. Agenus Inc Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 58. Novogene Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 59. ZIOPHARM Oncology Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 60. ISA Pharmaceuticals Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 61. BrightPath Biotherapeutics Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 62. Vaximm AG Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 63. Medigene AG Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 64. Genocea Biosciences Inc Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 65. Advaxis Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 66. Nouscom Revenue Growth Rate in Neoantigen Vaccine Business (2024-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed